Literature DB >> 30535331

Population-based cohort study assessing the efficacy of cervical cytology (Pap smear) and human papillomavirus (HPV) testing as modalities for cervical cancer screening.

Tohru Morisada1, Kumiko Saika2, Eiko Saito3, Kanako Kono4,2, Hiroshi Saito2, Daisuke Aoki1.   

Abstract

In cervical cancer screening, several trials have shown that human papillomavirus (HPV) testing or combined HPV testing and cytology leads to earlier detection of cervical intraepithelial neoplasia Grade 3 or worse (CIN3+) compared with cytology alone. However, the availability of similar evidence in our country remains limited. In 2013, 34 local governments were selected to administer a cervical cancer screening program utilizing either cytology alone or in combination with HPV testing. We planned a cohort study to assess the effectiveness of HPV testing as a modality for cervical cancer screening. The primary outcome of this study was the incidence of CIN3+ in each group, as well as to assess the risks and benefits of receiving screening for women in both groups. These results will contribute to elucidating the details of the positive and negative impacts of introducing HPV testing into a population-based cervical cancer screening program in Japan.

Entities:  

Mesh:

Year:  2018        PMID: 30535331     DOI: 10.1093/jjco/hyy025

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  2 in total

1.  Human papillomavirus testing as a primary screening tool for cervical cancer.

Authors:  Hyun Woong Cho; Jin Hwa Hong; Jae Kwan Lee
Journal:  J Gynecol Oncol       Date:  2021-05       Impact factor: 4.401

2.  The first-round results of a population-based cohort study of HPV testing in Japanese cervical cancer screening: baseline characteristics, screening results, and referral rate.

Authors:  Kanako Kono; Tohru Morisada; Kumiko Saika; Eiko Saitoh Aoki; Etsuko Miyagi; Kiyoshi Ito; Hirokazu Takahashi; Tomio Nakayama; Hiroshi Saito; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2021-01-26       Impact factor: 4.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.